CI

e-med
www.e-med.org.uk

EDITORIAL

Current role of radionuclide imaging in differentiated thyroid cancer

K.T. Wong[a], Frankie P.T. Choi[b], Yolanda Y.P. Lee[a] and Anil T. Ahuja[a]

[a]Department of Diagnostic Radiology & Organ Imaging, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR; [b]Department of Radiology, North District Hospital, Hong Kong SAR

Corresponding address: Professor Anil T. Ahuja, Department of Diagnostic Radiology & Organ Imaging, The Chinese University of Hong Kong, Prince of Wales Hospital, 30−32 Ngan Shing Street, Shatin N.T., Hong Kong SAR.
Email: aniltahuja@cuhk.edu.hk

Abstract

Nuclear medicine plays an integral role in the management of differentiated thyroid cancer. This editorial aims to provide a summary of the current role of radionuclide imaging, including whole body iodine scan and fluorodeoxy-glucose (FDG)-positron emission tomography (PET), in the diagnostic work-up and follow-up of patients with thyroid cancer.

Keywords: *Nuclear medicine; thyroid cancer.*

Thyroid nodules are a common clinical dilemma. The prevalence of a palpable thyroid nodule is approximately 5% in women and 1% in men in iodine-sufficient parts of the world[1,2]. The main aim in evaluating thyroid nodules is to detect thyroid cancer that occurs in 5−10% depending on age, gender, history of radiation exposure, family history and other factors[3,4]. More than 90% of thyroid cancers are differentiated, comprising papillary and follicular carcinoma[5].

High resolution ultrasound is the most common and ideal initial imaging investigation for thyroid nodules[6,7]. Combining ultrasound with guided fine needle aspiration cytology (FNAC) markedly improves its specificity and diagnostic accuracy. In particular the positive predictive value of FNAC is very high and this plays a major role in the management of thyroid cancer[8−10]. Conventional radionuclide thyroid scanning using [99mTc]pertechnetate or ^{123}I can determine whether a nodule is hyperfunctioning ('hot'), isofunctioning ('warm') or hypo/non-functioning ('cold') when the serum thyrotropin (TSH) level is subnormal or FNAC is indeterminate. A hot nodule is almost always benign and does not require further diagnostic evaluation[11]. Other radiotracers with

affinity for neoplastic lesions, such as ^{201}Tl, [99mTc]sestamibi, [99mTc]tetrofosmin, can be employed to characterize suspicious nodules[12−17], but are being increasingly supplanted by [^{18}F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in recent years[18−24]. There is no clear-cut differentiation between malignant and benign thyroid nodules by these radiotracers. However, FDG-PET and [99mTc]sestamibi scintigraphy (because of their high negative predictive values) may help to reduce unnecessary thyroidectomies for cytologically indeterminate thyroid nodules[17,22,23].

With the exception of low-risk unifocal microcarcinoma, total thyroidectomy followed by radioiodine ablation and TSH-suppressive thyroid hormone therapy is the standard treatment for differentiated thyroid cancers[25−27]. The benefits of prophylactic 'en bloc' central node dissection in the absence of pre- and intra-operative evidence for nodal disease remain controversial. Sentinel lymph node (SLN) biopsy has been advocated to avoid the morbidity of routine nodal dissection but allow the identification of draining nodes from the tumour and detection of micrometastases. These nodes can be located with preoperative lymphoscintigraphy

followed by intraoperative hand-held gamma probe[28]. SLN biopsy may play a role in early small thyroid cancers and larger clinical trials are awaited.

TSH-stimulated thyroglobulin, measured by sensitive immunoradiometric assays, provides one of the most sensitive means for detection of persistent disease in the absence of interfering anti-thyroglobulin antibodies[29]. For follow-up after standard treatment, a combination of TSH-stimulated thyroglobulin and ultrasound of the neck +/− FNAC are often sufficient in low-risk patients[30]. For high-risk patients or in cases of increasing TSH-stimulated thyroglobulin, radioiodine whole body scan (WBS) or FDG-PET is recommended for detection of persistent or metastatic disease.

Post-therapy WBS, performed 3−10 days after a therapeutic dose (30−100 mCi or more) of ^{131}I, helps to determine the extent of disease, predict prognosis and identify patients requiring additional workup. Post-therapy WBS has a higher diagnostic yield than pre-therapy diagnostic WBS in 10−50% of patients[31−35], the latter being acquired with a low radioiodine dose (1−5 mCi, typically less than 3 mCi) in order to minimize 'stunning' of thyroid cancer from responding to ensuing ^{131}I therapy[36−38]. Such concern about ^{131}I-induced stunning has led to an increasing trend of avoiding pre-therapy diagnostic ^{131}I WBS altogether, or considering the use of ^{123}I instead of ^{131}I for diagnostic WBS[39−41]. Iodine-123 has no beta (β) emission hence lesser thyroid stunning and no therapeutic value, yet it emits gamma (γ) energy with better imaging characteristics. It is, however, more expensive and not universally available.

Diagnostic radioiodine WBS during follow-up can help to assess the effectiveness of previous radioiodine ablation or treatment, and the requirement of further ^{131}I therapy for residual iodine-avid lesions in the thyroid bed or metastatic sites[42]. Diagnostic radioiodine WBS must be performed under endogenous or exogenous TSH stimulation (by 4-week withdrawal of levothyroxine or 2-day intramuscular administration of recombinant human thyrotropin). Its diagnostic sensitivity is relatively low (compared with post-therapy WBS), depending on the radioiodine dose and histological type, ranging from 45 to 75%, whereas the specificity is generally above 95%[43−46].

Radioiodine WBS, albeit with high diagnostic specificity, offers limited anatomical details with myriad pitfalls, such as physiologic uptake or secretion in various organs (salivary gland, nose, stomach, liver, breast, etc.), gastro-intestinal and urinary excretion, serous cavities or cysts, inflammation or infection, and non-thyroidal neoplasms[47]. To circumvent these problems, it is useful to perform single photon emission computed tomography (SPECT) to supplement planar scintigraphy. Precise anatomical localization of radioiodine uptake can further be achieved by co-registration with transmission CT images, which can readily be obtained with hybrid SPECT/CT imaging system available nowadays[48].

The incremental value of SPECT/CT was found to have therapeutic impact on 25−41% of patients with thyroid cancer[49−51]. Caution should be taken against the use of iodinated CT contrast that affects subsequent diagnostic or therapeutic application of radioiodine.

In less or de-differentiated thyroid cancer, recurrent or metastatic tumour cells may lose the expression of sodium iodide symporter and decreased ability to concentrate radioiodine[52]. In these circumstances, FDG-PET becomes a valuable investigation, especially in cases of elevated thyroglobulin and negative diagnostic or even post-therapy radioiodine WBS[53−56]. A multicentre series by Grünwald et al. found a higher sensitivity by FDG-PET (75%) than ^{131}I WBS (50%) and [^{99m}Tc]sestamibi/^{201}Tl WBS (53%) with comparable specificities[57]. The sensitivity of FDG-PET increased to 85% in the subgroup of patients with negative ^{131}I WBS. Robbins et al. documented significant inverse relationship between survival and both the FDG avidity of the most active lesion and the number of FDG-avid lesions[58].

Although FDG-PET serves an important role in the follow-up of patients with thyroid cancer, accurate localization of FDG-positive lesions is often difficult. Like SPECT/CT, the advent of hybrid PET/CT scanners has increased diagnostic confidence and reduced equivocal results in either PET or CT alone. Pitfalls of PET such as uptake in normal structures, bowel activity, urinary excretion of tracers, presence of brown fat are reduced[59]. Several recent studies have confirmed the value of PET/CT in differentiated thyroid cancer, especially those thyroglobulin-positive but iodine-negative cases, altering clinical management in 23−51% of cases[60−65].

For decades, nuclear medicine has had a major role in the management of differentiated thyroid cancer. The increasing availability of FDG-PET or PET/CT has expanded the armamentarium of the radionuclide imaging modality, complementing the well-established radioiodine scans towards the diagnosis, staging and follow-up of thyroid cancers. With advancement of hardware and development of radiopharmaceuticals or molecular probes, the potential scope of nuclear medicine in oncology continues to expand, further enhancing its role in the management of thyroid cancer.

References

[1] Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7: 481−93.

[2] Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968; 69: 537−40.

[3] Hegedüs L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351: 1764−71.

[4] Mandel SJ. A 64-year-old woman with a thyroid nodule. JAMA 2004; 292: 2632−42.

[5] Sherman SI. Thyroid carcinoma. Lancet 2003; 361: 501−11.

[6] Ahuja AT. The thyroid, parathyroids. In: Ahuja AT, Evans RM, editors. Practical head and neck ultrasound. London: Greenwich Medical Media Limited; 2000, p. 35–64.

[7] Watters DA, Ahuja AT, Evans RM, *et al*. Role of ultrasound in the management of thyroid nodules. Am J Surg 1992; 164: 654–7.

[8] Alexander EK, Heering JP, Benson CB, *et al*. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002; 87: 4924–7.

[9] Carmeci C, Jeffrey RB, McDougall IR, Nowels KW, Weigel RJ. Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. Thyroid 1998; 8: 283–9.

[10] Mikosch P, Gallowitsch HJ, Kresnik E, *et al*. Value of ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in an endemic goitre area. Eur J Nucl Med 2000; 27: 62–9.

[11] Mansi L, Moncayo R, Cuccurullo V, Dottorini ME, Rambaldi PF. Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer. Q J Nucl Med Mol Imaging 2004; 48: 82–95.

[12] el-Desouki M. Tl-201 thyroid imaging in differentiating benign from malignant thyroid nodules. Clin Nucl Med 1991; 16: 425–30.

[13] Sundram FX, Mack P. Evaluation of thyroid nodules for malignancy using ^{99m}Tc-sestamibi. Nucl Med Commun 1995; 16: 687–93.

[14] Mezosi E, Bajnok L, Gyory F, *et al*. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the differential diagnosis of cold thyroid nodules. Eur J Nucl Med 1999; 26: 798–803.

[15] Kresnik E, Gallowitsch HJ, Mikosch P, Gomez I, Lind P. Technetium-99m-MIBI scintigraphy of thyroid nodules in an endemic goiter area. J Nucl Med 1997; 38: 62–5.

[16] Kresnik E, Gallowitsch HJ, Mikosch P, *et al*. Evaluation of thyroid nodules with technetium-99m tetrofosmin dual-phase scintigraphy. Eur J Nucl Med 1997; 24: 716–21.

[17] Hurtado-López LM, Arellano-Montaño S, Torres-Acosta EM, *et al*. Combined use of fine-needle aspiration biopsy, MIBI scans and frozen section biopsy offers the best diagnostic accuracy in the assessment of the hypofunctioning solitary thyroid nodule. Eur J Nucl Med Mol Imaging 2004; 31: 1273–9.

[18] Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993; 114: 728–34.

[19] Uematsu H, Sadato N, Ohtsubo T, *et al*. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med 1998; 39: 453–9.

[20] Mitchell JC, Grant F, Evenson AR, Parker JA, Hasselgren PO, Parangi S. Preoperative evaluation of thyroid nodules with ^{18}FDG-PET/CT. Surgery 2005; 138: 1166–74.

[21] Kresnik E, Gallowitsch HJ, Mikosch P, *et al*. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 2003; 133: 294–9.

[22] de Geus-Oei LF, Pieters GF, Bonenkamp JJ, *et al*. ^{18}F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 2006; 47: 770–5.

[23] Sebastianes FM, Cerci JJ, Zanoni PH, *et al*. Role of ^{18}F-FDG PET in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2007; 92: 4485–8.

[24] Kim JM, Ryu JS, Kim TY, *et al*. ^{18}F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab 2007; 92: 1630–4.

[25] Pacini P, Schlumberger M, Dralle H, *et al*. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787–803.

[26] Cooper DS, Doherty GM, Haugen BR, *et al*. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 1–33.

[27] British Thyroid Association guidelines for the management of thyroid cancer, 2nd ed. London: Royal College of Physicians; 2007.

[28] Rubello D, Pelizzo MR, Al-Nahhas A, *et al*. The role of sentinel lymph node biopsy in patients with differentiated thyroid carcinoma. Eur J Surg Oncol 2006; 32: 917–21.

[29] Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98–105.

[30] Schlumberger M, Berg G, Cohen O, *et al*. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004; 150: 105–12.

[31] Fatourechi V, Hay ID, Mullan BP, *et al*. Are post-therapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000; 10: 573–7.

[32] Sherman SI, Tielens ET, Sostre S, Wharam Jr MD, Ladenson PW. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 629–34.

[33] Reynolds JC. Percent ^{131}I uptake and post-therapy ^{131}I scans: their role in the management of thyroid cancer. Thyroid 1997; 7: 281–4.

[34] Souza Rosário PW, Barroso AL, Rezende LL, *et al*. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med 2004; 29: 795–8.

[35] Pace L, Klain M, Albanese C, *et al*. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imaging 2006; 33: 179–183.

[36] Muratet JP, Giraud P, Daver A, Minier JF, Gamelin E, Larra F. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. J Nucl Med 1997; 38: 1362–8.

[37] Leger FA, Izembart M, Dagousset F, *et al*. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25: 242–6.

[38] Lassmann M, Luster M, Hänscheid H, Reiners C. Impact of ^{131}I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004; 45: 619–25.

[39] Yaakob W, Gordon L, Spicer KM, Nitke SJ. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases. J Nucl Med Technol 1999; 27: 279–81.

[40] Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26: 6–9.

[41] Silberstein EB. Comparison of outcomes after ^{123}I versus ^{131}I preablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 2007; 48: 1043–6.

[42] Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000; 85: 175–8.

[43] van Sorge-van Boxtel RA, van Eck-Smit BL, Goslings BM. Comparison of serum thyroglobulin, ^{131}I and ^{201}Tl scintigraphy in the postoperative follow-up of differentiated thyroid cancer. Nucl Med Commun 1993; 14: 365–72.

[44] Filesi M, Signore A, Ventroni G, Melacrinis FF, Ronga G. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med 1998; 39: 1542–6.

[45] Franceschi M, Kusić Z, Franceschi D, Lukinac L, Rončević S. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1996; 37: 446–51.

[46] Lubin E, Mechlis-Frish S, Zatz S, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994; 35: 257–62.

[47] Shapiro B, Vittoria R, Ayman J, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med 2000; 30: 115–32.

[48] Seo Y, Mari C, Hasegawa BH. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med 2008; 38: 177–98.

[49] Tharp K, Israel O, Hausmann J, et al. Impact of I-131 SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 1435–42.

[[50] Ruf J, Lehmkuhl L, Bertram H, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun 2004; 25: 1177–82.

[51] Even-Sapir E, Keidar Z, Sachs J, et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med 2001; 42: 998–1004.

[52] Min JJ, Chung JK, Lee YJ, et al. Relationship between expression of the sodium/iodide symporter and ^{131}I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001; 28: 639–45.

[53] Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468–72.

[54] Grünwald F, Menzel C, Bender H, et al. Comparison of [18]FDG-PET with [131]iodine and ^{99m}Tc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997; 7: 327–35.

[55] Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999; 9: 797–804.

[56] Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative ^{131}I scan. J Nucl Med 2001; 42: 71–6.

[57] Grünwald F, Kälicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26: 1547–52.

[58] Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[^{18}F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91: 498–505.

[59] Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in [18]FDG PET and PET/CT oncologic imaging. Semin Nucl Med 2004; 34: 122–33.

[60] Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005; 115: 237–43.

[61] Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006; 47: 616–24.

[62] Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2007; 34: 487–95.

[63] Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 2007; 32: 690–5.

[64] Shammas A, Degirmenci B, Mountz JM, et al. ^{18}F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007; 48: 221–6.

[65] Zuijdwijk MD, Vogel WV, Corstens FHM, Oyen WJG. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. Nucl Med Commun 2008; 29: 636–41.